Overview

Biocidium’s primary focus is the development of antibiotics to treat serious multi-drug resistant (MDR) gram-positive and gram-negative bacterial infections. Biocidium maintains strong antifungal and oncology programs and continues to build positive results in areas of skin treatments including psoriasis, acne, shingles and eczema. Biocidium has a significant IP portfolio, built over decades with a focus on bio-pharma solutions. Biocidium’s proprietary high efficacy/low toxicity antibiotics represent innovative advances in a bio-based comprehensive solution to these harmful diseases. Biocidium is one of the only companies that has developed both individual and combined gram-positive and gram-negative antibiotics. Biocidium fully understands the responsibility it has to develop, register and treat live threatening bacteria and conditions. Our work allows us the opportunity to help many patients by developing solutions that are both stand-alone, and compounds based on our extensive expertise. Biocidium’s antibiotics have shown 99.99999% efficacy against gram-negative and gram-positive drug-resistant organisms including: • CRE (Carbapenem-resistant Enterobacteriaceae) • VRE (Vancomycin-resistant Enterococcus) • DRS (Drug-resistant Shigella) • MRSA (Methicillin-resistant Staphylococcus aureus) • VRSA (Vancomycin-resistant Staphylococcus aureus) • MDPA (Multidrug-resistant Pseudomonas aeruginosa) • DRNG (Drug-resistant Neisseria gonorrhoeae)